Standout Papers

New response evaluation criteria in solid tumours: Revised RECIST guidelin... 2003 2026 2010 2018 20.1k
  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) (2008)
    E. Eisenhauer, P. Therasse et al. European Journal of Cancer
  2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2012)
    Axel Grothey, Eric Van Cutsem et al. The Lancet
  3. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer (2003)
    Richard M. Goldberg, Daniel J. Sargent et al. Journal of Clinical Oncology
  4. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer (2003)
    Christine Ribic, Daniel J. Sargent et al. New England Journal of Medicine
  5. Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (2010)
    Daniel J. Sargent, Silvia Marsoni et al. Journal of Clinical Oncology
  6. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. (2000)
    Carolyn C. Compton, L P Fielding et al. PubMed
  7. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy (2009)
    Scott Kopetz, George J. Chang et al. Journal of Clinical Oncology
  8. Prognostic Factors in Colorectal Cancer (2000)
    Carolyn C. Compton, L P Fielding et al. Archives of Pathology & Laboratory Medicine
  9. Guidelines 2000 for Colon and Rectal Cancer Surgery (2001)
    Nicholas J. Petrelli, Arthur M. Carlin et al. JNCI Journal of the National Cancer Institute
  10. Laparoscopic Colectomy for Cancer Is Not Inferior to Open Surgery Based on 5-Year Data From the COST Study Group Trial (2007)
    James W. Fleshman, Daniel J. Sargent et al. Annals of Surgery
  11. Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment (2004)
    Axel Grothey, Daniel J. Sargent et al. Journal of Clinical Oncology
  12. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? (2004)
    Sharlene Gill, Charles L. Loprinzi et al. Journal of Clinical Oncology
  13. A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients (2001)
    Daniel J. Sargent, Richard M. Goldberg et al. New England Journal of Medicine
  14. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials (2005)
    Daniel J. Sargent, Harry S. Wieand et al. Journal of Clinical Oncology
  15. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) (2008)
    Axel Grothey, Mary M. Sugrue et al. Journal of Clinical Oncology
  16. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database (2016)
    Jan Franko, Qian Shi et al. The Lancet Oncology
  17. Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 (2011)
    Jan Franko, Qian Shi et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 7 from Science/Nature 84 standout
Sub-graph 1 of 18

Citing Papers

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
2023 StandoutNature
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2023 Standout
7 intermediate papers

Works of Daniel J. Sargent being referenced

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Optimising the design of phase II oncology trials: The importance of randomisation
2008
and 5 more

Author Peers

Author Last Decade Papers Cites
Daniel J. Sargent 37110 11632 3148 17777 12411 474 57.2k
Jaap Verweij 27869 4537 805 21972 8677 619 54.4k
Lawrence H. Schwartz 20632 6756 550 20087 8158 386 50.1k
Larry Rubinstein 22032 2951 1894 19844 7219 195 46.6k
Mithat Gönen 25916 3540 974 18942 20330 769 58.9k
Richard Kaplan 22048 3794 871 19835 7599 171 45.0k
Josep Tabernero 33324 9222 357 14187 7861 1.1k 49.1k
Eric Van Cutsem 68215 15802 636 35069 20117 1.2k 92.5k
Janet Dancey 19412 3277 672 15054 5384 202 37.3k
Seth M. Steinberg 28549 7877 321 13347 6251 861 57.6k
John D. Hainsworth 21144 6869 271 12105 5165 623 36.4k

All Works

Loading papers...

Rankless by CCL
2026